Correction to: Adv Ther (2020) 37:1812–1828 10.1007/s12325-020-01289-y
In the Original Article, Table 4 was published incorrectly. The correct Table 4 is given below.
Table 4.
Drug combinations, devices and doses for treating patients with stable COPD in the GOLD reports, 2001–2020
| Drug | Inhaler (μg) | Solution for nebulizer (mg/ml) | Duration of action (h) |
|---|---|---|---|
| Combination short-acting β2-agonists plus anticholinergic in one inhaler | |||
| Fenoterol/Ipratropiuma | 200/80 (pMDI) | 1.25/0.5 in 4 ml | 6–8 |
| Albuterol/Ipratropiuma | 75/15 (pMDI)b | 0.75/4.5 → 0.5, 2.5 in 3 mlc | 6–8 |
| 100/20 (SMI)d | 6–8 | ||
| Combination long-acting β2-agonists plus anticholinergic in one inhaler | |||
| Indacaterol/glycopyrroniume | 85/43 (DPI) | 24 | |
| Vilanterol/umeclidiniumf | 25/62.5 (DPI) | 24 | |
| Formoterol/aclidiniumg | 12/340 (DPI) | 12 | |
| Olodaterol/tiotropiumh | 5/5 (SMI) | 24 | |
| Formoterol/glycopyrroniumi | 9.6/14.4 → 9.6/18 (pMDI) | 12 | |
| Formoterol/glycopyrrolatej | 4.8/9 | 12 | |
| Combination long-acting β2-agonists plus glucocorticosteroids in one inhaler | |||
| Formoterol/Budesonidek | 4.5/160 (pMDI) | ||
| 9/320 (DPI) | |||
| Formoterol/mometasonel | 10/200, 10/400 (pMDI) | ||
| Salmeterol/Fluticasonem | 50/100, 250, 500 (DPI) | ||
| 25/50, 125, 250 (pMDI) | |||
| Vilanterol/Fluticasone furoaten | 25/100 (DPI) | ||
| Formoterol/Beclomethasoneo | 6/100 (pMDI & DPI) | ||
| Triple Combination in one device (LABA/LAMA/ICS)p | |||
| Fluticasone/umeclidinium/vilanterolq(DPI) | |||
| Beclometasone/formoterol/glycopyrroniumr (pMDI) | |||
Specific doses were no longer shown in “Commonly Used Maintenance Medications in COPD” after 2018
aCombination added in 2003
bpMDI formulation for Albuterol/Ipratropium combination was discontinued after 2013
cAlbuterol/Ipratropium combination solution for nebulizer was changed to 0.75/0.5 in 2010, discontinued in 2013, and added back as 0.5, 0.25 mg/ml in 2017
dA soft mist inhaler (SMI) formulation for Albuterol/Ipratropium combination (100/20 μg) was added in 2014
eIndacaterol/glycopyrronium combination was added in 2014
fVilanterol/umeclidinium combination was added in 2014
gFormoterol/aclidinium combination was added in 2015
hOlodaterol/tiotropium combination was added in 2017
iFormoterol/glycopyrronium combination was added in 2017; dose was changed to 9.6/18 in 2018
jFormoterol/glycopyrrolate combination was added in 2018
kFormoterol/Budesonide combination was added in 2003
lFormoterol/Mometasone combination was added in 2013
mSalmeterol/Fluticasone combination was added in 2003
nVilanterol/Fluticasone combination was added in 2014
oFormoterol/Beclomethasone combination was added in 2015 for pMDI; DPI formulation was added in 2016
pTriple therapy was added to GOLD’s “Commonly Used Maintenance Medications in COPD” table in the 2019 Report
qFluticasone/umeclidinium/vilanterol combination was added in 2019 (doses and devices were not specified)
rBeclometasone/formoterol/glycopyrronium combination was added in 2019 (doses and devices were not specified)